Healthcare entity
Hims & Hers is most often covered alongside Eli Lilly, which appears in 1 of these 2 stories. The 17-day window averages about 0.8 stories each week. The 7 average consequence score is above the beat benchmark of 5.8 in the same window.
Last mentioned: Mar 12, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Hims & Hers is most often covered alongside Eli Lilly, which appears in 1 of these 2 stories. The 17-day window averages about 0.8 stories each week. The 7 average consequence score is above the beat benchmark of 5.8 in the same window. They are less corroborated than the beat average, carrying 2.5 original sources each against 3.3 for the same window. acquisition accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. This profile follows 2 Healthcare stories mentioning Hims & Hers across the period from February 24, 2026 to March 12, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 344 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Hims & Hers. Shared-story counts are live from our verified record — not editorial picks.
Global Market Reaction
Industry analysts note the deal as a major consolidation in the GLP-1 and telehealth sectors.
Payout Details Emerge
Former CCO Joe Harris confirms a payout exceeding $1 million, highlighting the impact on staff wealth.
Acquisition Announced
Hims & Hers officially announces the $1.6 billion buyout of Sydney-based Eucalyptus.
The FDA has issued a formal warning letter to Novo Nordisk for failing to properly report serious adverse events, including deaths and strokes, related to its GLP-1 medications. This regulatory escalation coincides with a significant market valuation decline and intensifying competition from compounding pharmacies.
Source: gulfcoastnewsnow.com · koco.com
US telehealth leader Hims & Hers has finalized a $1.6 billion acquisition of Australian digital health startup Eucalyptus, marking a major expansion into the Asia-Pacific market. The deal, driven by the explosive growth of GLP-1 weight-loss treatments, creates over 100 employee millionaires and solidifies Hims & Hers' position as a global powerhouse in direct-to-consumer healthcare.
Hims & Hers is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
